BGM Group Ltd. (BGM) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

BGM Group Ltd. (BGM) Healthcare & Pipeline Overview

BGM Group Ltd., based in China, manufactures and distributes APIs, TCMDs, and other by-products, including licorice extracts and organic fertilizers. With a market capitalization of $100M, BGM serves pharmaceutical and agricultural sectors, facing competition in the specialty and generic drug manufacturing industry.

What Is the Investment Thesis for BGM?

BGM Group Ltd. presents a complex investment case. The company's diverse product portfolio, ranging from pharmaceuticals to agricultural products, offers diversification but also introduces operational complexity. With a market capitalization of $100M, BGM operates in a competitive landscape. The company's negative profit margin of -5.7% raises concerns about profitability, while a gross margin of 16.4% indicates some pricing power. A beta of 1.93 suggests high volatility relative to the market. Key growth catalysts include expansion within the Chinese pharmaceutical and agricultural markets. However, investors should carefully consider the risks associated with operating in a regulated industry and the company's current financial performance.

Based on FMP financials and quantitative analysis

BGM Key Highlights

Market capitalization of $100M indicates a small-cap company with potential for growth but also higher risk.

• Negative profit margin of -5.7% signals challenges in achieving profitability and efficient cost management.
• Gross margin of 16.4% suggests some ability to control production costs but lower than industry leaders.
• Beta of 1.93 indicates higher volatility compared to the overall market, potentially driven by its small size and industry factors.
• No dividend yield reflects a focus on reinvesting earnings for growth rather than returning capital to shareholders.

Who Are BGM's Competitors?

BGM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BGM's Key Strengths?

Diverse product portfolio across pharmaceuticals and agriculture.

• Established presence in the Chinese market.
• Manufacturing capabilities for APIs and TCMDs.

What Are BGM's Weaknesses?

Negative profit margin.

• High beta indicating significant volatility.
• Limited international presence.

What Could Drive BGM Stock Higher?

Potential regulatory approvals for new pharmaceutical products.

• Expansion of distribution network in China.
• Increasing demand for organic fertilizers in the agricultural sector.

What Are the Key Risks for BGM?

Negative return on equity (-3.4%) — the business is not currently generating profit on shareholder capital.

• Changes in Chinese regulations affecting the pharmaceutical and agricultural industries.
• Increased competition from domestic and international players.
• Fluctuations in raw material prices.
• Negative profit margin impacting financial stability.

What Are the Growth Opportunities for BGM?

• Expansion of API Manufacturing: BGM can capitalize on the growing demand for active pharmaceutical ingredients (APIs) in China. The Chinese API market is projected to reach $50 billion by 2028, driven by the increasing production of generic drugs and the rising demand for innovative therapies. BGM can invest in expanding its API manufacturing capacity and developing new APIs to cater to this growing market. Timeline: 2-3 years.
• Increased Penetration of Traditional Chinese Medicine (TCM) Market: The market for TCM is expanding both domestically and internationally. BGM can leverage its existing TCMD products, such as Ahan antibacterial paste, to capture a larger share of this market. The global TCM market is expected to reach $60 billion by 2027. BGM can focus on developing new TCM products and expanding its distribution network to reach a wider customer base. Timeline: Ongoing.
• Growth in Organic Fertilizer Segment: With increasing awareness of sustainable agriculture practices, the demand for organic fertilizers is rising. BGM can expand its production and marketing of Xiongguan organic fertilizers to capitalize on this trend. BGM can focus on developing high-quality organic fertilizers and establishing partnerships with farmers and agricultural cooperatives. Timeline: 1-2 years.
• Strategic Partnerships and Acquisitions: BGM can pursue strategic partnerships or acquisitions to expand its product portfolio, geographic reach, and technological capabilities. This could involve partnering with other pharmaceutical companies, agricultural companies, or research institutions. By forming strategic alliances, BGM can gain access to new markets, technologies, and expertise. Timeline: Ongoing.
• International Expansion: BGM can explore opportunities to expand its operations beyond China. This could involve exporting its products to other countries or establishing manufacturing facilities in new markets. The global pharmaceutical and agricultural markets offer significant growth potential. BGM can focus on identifying markets with favorable regulatory environments and strong demand for its products. Timeline: 3-5 years.

What Threats Does BGM Face?

• Intense competition from established pharmaceutical companies.
• Stringent regulatory requirements.
• Fluctuations in raw material prices.

What Are BGM's Competitive Advantages?

• Established presence in the Chinese pharmaceutical and agricultural markets.
• Diverse product portfolio spanning pharmaceuticals, TCMDs, and agricultural products.
• Proprietary manufacturing processes for certain APIs and TCMDs.

What Does BGM Do?

BGM Group Ltd, formerly known as Qilian International Holding Group Limited, was incorporated in 2019 and is headquartered in Chengdu, China. The company operates within the healthcare sector, focusing on the manufacturing and distribution of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and various by-products. BGM's product portfolio includes licorice products such as Gan Di Xin, Qilian Shan Licorice Extract, and Qilian Shan licorice liquid extract, catering to pharmaceutical companies and medical preparation companies. Additionally, BGM offers Qilian Shan oxytetracycline tablets and APIs, addressing disease prevention and treatment in animals and humans. Beyond pharmaceuticals, BGM produces TCMD products like Ahan antibacterial paste and heparin products for cardiovascular and cerebrovascular applications. The company also manufactures Zhu Xiaochang sausage casings, targeting the culinary sector. Furthermore, BGM extends its reach into agriculture with Xiongguan organic fertilizers and organic-inorganic compound fertilizers, aimed at improving crop yield and soil quality. BGM's diverse product range reflects its strategic approach to serving multiple sectors within the Chinese market. The company changed its name to BGM Group Ltd in October 2024, marking a new chapter in its corporate evolution.

What Products and Services Does BGM Offer?

• Manufactures and distributes active pharmaceutical ingredients (APIs).
• Produces traditional Chinese medicine derivatives (TCMD).
• Offers licorice products for pharmaceutical and medical applications.
• Provides oxytetracycline tablets and APIs for disease prevention and treatment.
• Manufactures heparin products for cardiovascular and cerebrovascular applications.
• Produces organic fertilizers for improving crop yield and soil quality.
• Offers sausage casings for culinary applications.

How Does BGM Make Money?

• BGM generates revenue through the sale of APIs to pharmaceutical companies.
• The company earns income from the distribution of TCMDs to healthcare providers and consumers.
• BGM profits from the sale of organic fertilizers to farmers and agricultural businesses.

What Industry Does BGM Operate In?

BGM Group Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, which is characterized by intense competition and regulatory scrutiny. The market is driven by factors such as an aging population, increasing healthcare expenditure, and the rising prevalence of chronic diseases. BGM competes with both domestic and international players, including companies like Edgewise Therapeutics, Inc. (EWTX). The industry is also subject to stringent regulations regarding drug safety, manufacturing standards, and pricing policies. Companies must continuously innovate and adapt to changing market dynamics to maintain a competitive edge.

Who Are BGM's Key Customers?

• Pharmaceutical companies that use BGM's APIs in their drug formulations.
• Healthcare providers who prescribe or recommend BGM's TCMDs.
• Farmers and agricultural businesses that use BGM's organic fertilizers.

Company Profile

BGM Group Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Chengdu, CN. The company is led by CEO Chen Xin. BGM has traded publicly since 2003.

BGM Revenue & Earnings Trend

In Q3 2025, BGM generated $23.6M in top-line revenue, marking a sequential increase of 65.0%. The company recorded a net loss of $19.1M, with diluted EPS of $-0.15. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company.

BGM Group Ltd. (BGM) Valuation Context

Valued at $100M, BGM is classified as a micro-cap stock. Relative to its peer group, BGM's quantitative score of 42/100 is below the peer average of 64/100.

Return on equity for BGM Group Ltd. stands at -3.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -47.0%, the inverse of the P/E and a quick read on earnings relative to price.

BGM Financials

BGM Latest News

BGM Analyst Consensus

BGM MoonshotScore

BGM Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources